MULTIPLE MYELOMA; Peter's appeal for treatment rejected by NHS Trust.
It affects plasma cells in bone marrow, with symptoms including bone pain, fractures, fatigue, anaemia and an increased susceptibility to infection.
The Myeloma UK support group said Revlimid is one of the most important treatment breakthroughs in the past 40 years.
A spokeswoman for Myeloma UK said: "It is the first myeloma treatment to be developed where the balance between clinical effectiveness and sideeffects is excellent.
"Revlimid can improve overall survival with myeloma by up to three years."
|Printer friendly Cite/link Email Feedback|
|Publication:||South Wales Echo (Cardiff, Wales)|
|Date:||Nov 22, 2008|
|Previous Article:||'I've enough on my plate with fighting cancer, now I have to fight the NHS' Peter's appeal for treatment rejected by NHS Trust.|
|Next Article:||My, my, how can I resist you... Hairdressing trio star in prime-time TV advert.|